Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06471842

Study of the Prevalence of Pediatric Eating Disorders in Inherited Metabolic Diseases With Dietary Treatment

The main objective of this study is to estimate the prevalence of Pediatric Eating Disorders (PED) in Inherited Metabolic Diseases (IMD) with dietary treatment between the age of 12 months and 6 years 11 months.

Recruiting

Interested in participating?

Request Info

Key information

Age range

12 month–6 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Inherited Metabolic Diseases (IMDs) are rare conditions, which are the consequence of a genetic defect affecting an enzyme or a transporter involved in metabolism. This enzymatic defect leads to the accumulation of a potentially toxic compound located upstream of the deficiency and/or the absence of a compound located downstream of the defect. Treatment is possible and it consists of dietary and/or drug treatment.

Pediatric Eating Disorders (PED) cover "all the difficulties of oral feeding. These may be disorders due to absence of spontaneous feeding behavior, or refusal to eat, and disorders which affect the child's entire psychomotor, language and emotional development.

To date, the investigators note the absence of data on the prevalence of PED in IMDs and more generally on the quality of life and psychomotor development of these patients.

The causes and mechanisms of PED are numerous and heterogeneous. Their origins can be endogenous and/or exogenous.

Our main hypothesis is that the presence of PEDs varies depending on the different categories of IMDs with dietary treatment. Estimating their prevalence would enable awareness and early, better quality care.

This study aims to obtain clear and consistent results from a validated scale. It is a single-site study prospectively including patients from the Necker-Enfants Malades hospital reference center.

Parents will be informed of the study by an investigator (psychomotor therapist or dietician) during a phone call, by email or in hospital prior to the inclusion visit.

On the day of inclusion, the parent's and the child's (depending on their age) non-opposition will be collected before carrying out any procedure and recorded in the patient's medical file.

The MCH (Montreal children's hospital) scale and the parental questionnaire will be proposed by the study investigators at the same time, in a physical interview.

The collection of medical data in the patient's file and the rating of the MCH scale will be done in parallel by the study investigators.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient from 12 months to 6 years and 11 months old
  • Patient with an Inherited Metabolic Diseases with dietary treatment
  • Patient having experimented a dietary diversification at least 6 month prior
  • Patient whose parents do not object to their participation in the study

Exclusion criteria

  • Patient with an associated chronic disease
  • Patient with diagnosed Autistic Spectrum Disorder (ASD) or Pervasive Developmental Disorders (PDD)
  • Patient born before 36 weeks of amenorrhea
  • Patient with multiple disabilities
  • Patient with dystonia
  • Patient with absent or unstable head posture
  • Patient whose parents do not fully understand or speak French

Treatment and study plan

MCH (Montreal Children's Hospital) feeding scale questionnaire and parental questionnaire

Other

The patient's parents will answer the questionnaire and the investigator will complete the parental questionnaire while asking the questions.

Primary outcomes

  1. Feeding scale score

    Time frame: 1 day

    MCH (Montreal Children's Hospital) feeding scale score between the age of 12 months and 6 years 11 months.

Secondary outcomes

  1. Disorders severity level differentiation

    Time frame: 1 day

    Differentiation between severe/moderate/mild paediatric eating disorders (PED) using the MCH scale score. This scale makes it possible to differentiate the disorders severity level: mild PED with a score between 61 and 65, moderate PED with a score between 66 and 70 and severe PED with a score higher than or equal to 71.

  2. Paediatric eating disorders prevalence for each pathology

    Time frame: 1 day

    Estimate for each pathology the paediatric eating disorders prevalence using the MCH scale score

  3. Risk factors identification

    Time frame: 1 day

    Identify the paediatric eating disorders' risk factors which are inherent to the disease, environmental and psycho-affective based on the parental questionnaire created for this purpose and the data collected

Study contacts

Contact information is provided by the study sponsor or research team.

Gael PLASTOW

CONTACT

[email protected]

+33 144381857

Manon Tessier

CONTACT

[email protected]

+33 1 87 89 20 65

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • URC-CIC Paris Descartes Necker Cochin

Registry information

Acronym: MEAL

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jun 24, 2024
Registry last updated
Nov 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.